Labmanager Logo
3D render of blue, purple, red, and tan proteins

iStock, selvanegra

Developing Therapies for Duchenne Muscular Dystrophy

Study uncovers dystrophin-dystrobrevin interactions, paving new paths for Duchenne Muscular Dystrophy treatments

| 2 min read
Share this Article
Register for free to listen to this article
Listen with Speechify
0:00
2:00

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD).

Published in the December issue of the Journal of Biological Chemistry, researchers characterize the mysterious C-terminal (CT) domain of dystrophin and its role in stabilizing cellular membranes across various tissues.

Lab manager academy logo

Get training in Lab Crisis Preparation and earn CEUs.

One of over 25 IACET-accredited courses in the Academy.

Certification logo

Lab Crisis Preparation course

DMD, a severe genetic disorder that causes muscle weakness and shortens lifespans, arises from mutations in the gene encoding dystrophin. While current treatments can extend patients’ lifespans, their high cost and limited efficacy underscore the urgent need for broader therapeutic approaches.

“This research highlights the intricate dynamics of dystrophin and dystrobrevin interactions, providing critical insights that could inform future treatment development,” said Krishna Mallela, professor of pharmaceutical sciences at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and study lead author. “By understanding how these proteins function differently in various tissues, we’re one step closer to designing treatments that target the root causes of DMD.”

The study reveals that dystrophin’s CT domain interacts differently with the two major dystrobrevin isoforms, which bind to dystrophin. Variations in the amino acid composition of dystrobrevin proteins drive differences in binding affinity and interaction modes, influencing the stability of the dystrophin-associated protein complex across tissues, a key indication of DMD.

These findings offer a molecular explanation for the wide-ranging symptoms experienced by DMD patients, which extend beyond skeletal muscles to affect organs such as the heart and brain.

“This discovery is exceptional in advancing DMD care because, while there have been advancements in therapies, they have been approved in desperation. We need to get to the root of things to really hone in on effective treatments,” says Mallela. “Much like a car engine, how can you fix a car without understanding how the car engine functions?”

Interested in Life Science News?

Subscribe to our free Life Science Tools & Techniques newsletter.

Is the form not loading? If you use an ad blocker or browser privacy features, try turning them off and refresh the page.

-Note: This news release was originally provided by University of Colorado Anschutz Medical Campus. As it has been republished, it may deviate from our style guide.

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - December 2024

2025 Industry and Equipment Trends

Purchasing trends survey results

Lab Manager December 2024 Cover Image
Lab Manager Life Science eNewsletter

Stay Connected with Life Science News

Click below to subscribe to Life Science Tools & Techniques eNewsletter!

Subscribe Today